Skip to content
Find a Provider
Jonathan W. Friedberg, M.D., M.M.Sc.

Jonathan W. Friedberg, M.D., M.M.Sc.

Hematology & Oncology , Cancer

5 out of 5 stars
252 Ratings
45 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-5823
Fax (585) 784-7907
Administrative (585) 275-4911

Locations

Wilmot Cancer Center - Rochester

Strong Memorial Hospital
90 Crittenden Boulevard
Rochester, NY 14642

(585) 275-5830 Get Directions
Wilmot Cancer Institute - Webster

875 Hard Road
Webster, NY 14580

(585) 602-3150 Get Directions

About Me

As Director of the Wilmot Cancer Institute, I seek to provide the highest level of compassionate care for patients, ensuring access to novel treatments and clinical trials whenever possible. My background brings the entire continuum of lymphoma experience to patients, from diagnosis through all trea...
As Director of the Wilmot Cancer Institute, I seek to provide the highest level of compassionate care for patients, ensuring access to novel treatments and clinical trials whenever possible. My background brings the entire continuum of lymphoma experience to patients, from diagnosis through all treatments including autologous stem cell transplantation, CAR-T cell interventions, novel agents, and survivorship.

We have built an incredibly strong team in Rochester to care for patients with lymphoma that is absolutely first rate and internationally recognized. We have expertise in hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. Driving this team toward excellence – and seeing our success – is highly rewarding.

Lymphoma is a complex set of diseases that can affect any organ system and I was drawn to that challenge. Our understanding of blood cancers in general, and specifically lymphoma, has enabled us to cure a subset of patients – and that also attracted me to this specialty. Happily, this fraction of cured patients has substantially increased during my 20-plus years in this field. Since lymphoma can affect anyone – males, females, young patients, older patients, and all ethnicities – I am rewarded by the interaction with a variety of patients.

My practice team includes Anna Morrison, R.N., Kerri Hugelmaier, N.P.

Conditions I Treat:

- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Waldenstrom macroglobulinemia
- Chronic lymphocytic leukemia

Certified Specialties

Hematology - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Director - Cancer Center

Samuel E. Durand Chair in Medicine - Department of Medicine (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, Dana-Farber Cancer Institute. 1997 - 1999

Residency, Internal Medicine, Massachusetts General Hospital. 1995 - 1997

Internship, Internal Medicine, Massachusetts General Hospital. 1994 - 1995

Education

MD | Harvard Medical School. 1994

Awards

Faculty Academic Mentoring Award. 2012

Scholar in Clinical Research. 2008 - 2008

America's Top Doctors Selection. 2008 - 2008

Jacob Gitelman Award. 2007 - 2007

Lawrence A. Kohn Senior Teaching Fellow. 2004 - 2006

Clinical Investigator Career Development Award. 2003 - 2003

Clinical Oncology Research Fellowship " Immunotherapy of Hodgkin's Disease". 2001 - 2003

Rising stars program for innovative research. 2001 - 2003

Research

Clinical Trials

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

Lead Researcher: Jonathan W Friedberg MD

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

Lymphoma Epidemiology of Outcomes Cohort Years 6-10

Lead Researcher: Jonathan W Friedberg MD

The goal of this infrastructure protocol is to build and maintain a large and diverse observational cohort study to support broad and cutting-edge research focused on NHL prognosis and survivorship. The LEO cohort will promote identification of clini...

Publications

Journal Articles

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW

The New England journal of medicine.. 2024 October 17391 (15):1379-1389. Epub 1900 01 01.

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis.

Abro B, Maurer MJ, Habermann TM, Burack R, Chapman JR, Cohen JB, Friedberg JW, Inghirami GG, Kahl BS, Larson MC, Link BL, Lossos IS, Martin P, McDonnell T, Nastoupil LJ, Riska S, Syrbu SI, Vega F, Vij K, Flowers CR, Cerhan JR, Jaye DL, Feldman AL

Blood.. 2024 September 10 Epub 09/10/2024.

T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features.

El Hussein S, Fang H, Jelloul FZ, Wang W, Loghavi S, Miranda RN, Friedberg JW, Burack WR, Evans AG, Xu J, Medeiros LJ

Archives of pathology & laboratory medicine.. 2024 August 1148 (8):914-920. Epub 1900 01 01.

High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.

Peppone LJ, Kleckner AS, Fung C, Puzas JE, Reschke JE, Culakova E, Inglis J, Kamen C, Friedberg JW, Janelsins M, Mustian K, Heckler CE, Mohile S

Cancer.. 2024 July 15130 (14):2538-2551. Epub 03/23/2024.

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.

Batchelor TT, Giri S, Ruppert AS, Geyer S, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston ND, Nayak L, Leonard JP, Rubenstein JL

Blood advances.. 2024 June 258 (12):3189-3199. Epub 1900 01 01.

Clonally unrelated primary large B-cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune-privileged sites?

George GV, Aldowitz DG, Jajosky AN, Wallace DS, Burack WR, Friedberg JW, El Hussein S

EJHaem.. 2024 June 5 (3):599-602. Epub 04/24/2024.

Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.

Smith MR, Jegede O, Martin P, Till B, Parekh S, Yang DT, Hsi ED, Witzig TE, Dave SS, Scott DW, Hanson CA, Kostakoglu L, Abdel Samad NN, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum K, Romer M, Inwards DJ, Lerner R, Wagner L, Little RF, Friedberg JW, Leonard JP, Kahl BS

Blood.. 2024 May 31 Epub 05/31/2024.

Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma.

Upshaw JN, Nelson J, Sweigart B, Rodday AM, Kumar AJ, Konstam MA, Wong JB, Ky B, Karmiy S, Friedberg JW, Evens AM, Kent DM, Parsons SK

JACC. CardioOncology.. 2024 April 6 (2):200-213. Epub 04/16/2024.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.

Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR

American journal of hematology.. 2024 March 99 (3):408-421. Epub 01/13/2024.

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.

Friedberg JW, Bordoni RE, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia R, Cline VJM, Mamidipalli A, Liu J, Akyol A, Yasenchak C

Blood.. 2024 February 29143 (9):786-795. Epub 1900 01 01.

Classic Hodgkin Lymphoma in Adolescents and Young Adults.

Kelly KM, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2024 February 2042 (6):653-664. Epub 11/20/2023.

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM

Blood advances.. 2024 January 238 (2):378-387. Epub 1900 01 01.

Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.

Lo AC, Liu A, Liu Q, Yasui Y, Castellino SM, Kelly KM, Hererra AF, Friedberg JW, Friedman DL, Schwartz CL, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine LS, Hodgson DC

JAMA network open.. 2024 January 27 (1):e2351062. Epub 01/02/2024.

Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer.

O'Reilly EM, Ko AH, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 December 2041 (36):5479-5480. Epub 1900 01 01.

Understanding treatment decisions for Hodgkin lymphoma: a qualitative study.

Kumar AJ, Pearson LK, Wong JB, Friedberg JW, Parsons SK, LeClair AM

Leukemia & lymphoma.. 2023 December 64 (14):2249-2257. Epub 12/25/2023.

Common clonal origin of three distinct hematopoietic neoplasms in a single patient: B-cell lymphoma, T-cell lymphoma, and polycythemia vera.

Nkosi D, Allbee AW, Rothberg PG, Friedberg JW, Evans AG

Cold Spring Harbor molecular case studies.. 2023 December 9 (4)Epub 01/10/2024.

Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma.

Toner K, Allen CE, Jain S, Kahl B, Leonard J, Wasserstrom H, Friedberg JW, Seibel NL, Kelly K

EJHaem.. 2023 November 4 (4):921-926. Epub 09/07/2023.

Current directions in the treatment of classical Hodgkin lymphoma.

Keller FG, Kahl B, Friedberg JW

EJHaem.. 2023 November 4 (4):908-911. Epub 09/29/2023.

Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.

Brady MT, Laniewski N, Strawderman M, Chu CC, Kanagaiah P, Sangster MY, Topham DJ, Friedberg JW, Zent CS

American journal of hematology.. 2023 October 98 (10):E288-E290. Epub 07/23/2023.

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.

Lakhotia R, Dunleavy K, Abramson JS, Link BK, Powell BL, Melani C, Lucas AN, Steinberg SM, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Noy A, Wilson WH, Roschewski MJ

Blood advances.. 2023 September 267 (18):5320-5324. Epub 1900 01 01.

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.

Burack WR, Li H, Adlowitz DG, Spence JM, Rimsza LM, Shadman M, Spier C, Kaminski MS, Leonard JP, Leblanc M, Smith SM, Friedberg JW

Blood advances.. 2023 September 127 (17):5082-5090. Epub 1900 01 01.

Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.

Thapa K, Strawderman M, Reagan PM, Barr PM, Zent CS, Friedberg JW, Faugh T, Casulo C

Clinical lymphoma, myeloma & leukemia.. 2023 September 23 (9):e260-e267. Epub 05/23/2023.

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM

Leukemia & lymphoma.. 2023 September 64 (9):1579-1582. Epub 06/21/2023.

Use of Large Language Models and Artificial Intelligence Tools in Works Submitted to .

Miller K, Gunn E, Cochran A, Burstein H, Friedberg JW, Wheeler S, Frankel P

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 July 141 (19):3480-3481. Epub 05/18/2023.

A New Look as Looks to the Future.

Miller KD, Cochran A, Gunn E, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 July 141 (19):3478-3479. Epub 1900 01 01.

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM

Blood advances.. 2023 June 137 (11):2496-2503. Epub 1900 01 01.

Update on follicular lymphoma.

Friedberg JW

Hematological oncology.. 2023 June 41 Suppl 1 (Suppl 1):43-47. Epub 1900 01 01.

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.

Pinto AA, Bosch F, Bisneto JCV, Sanz RG, Garcia CG, Smith SD, Wallace DS, Arcaini L, Merryman R, Marolleau J, De Filippi R, Chêne L, Bonny C, Fagerberg J, Friedberg JW, Ansel S, Armand P, Zinzani PL

Hematological oncology.. 2023 June 41 Suppl 2 :581-582. Epub 1900 01 01.

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.

Amengual JE, Reagan P, Li H, Saeed H, Vaidya R, Unger JM, Danilov A, LeBlanc M, Friedberg JW, Smith SM

Hematological oncology.. 2023 June 41 Suppl 2 :842-843. Epub 1900 01 01.

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.

Brem EA, Li H, Beaven AW, Caimi P, Cerchietti L, Olin RL, Henry NL, Dilon H, Little RF, Leblanc ML, Kahl B, Leonard JP, Friedberg JW, Smith SM

Hematological oncology.. 2023 June 41 Suppl 2 :848-849. Epub 1900 01 01.

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.

Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Hodgson D, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum K, Perry AM, Kovach A, Constine LS, Shields LK, Prica A, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW

Hematological oncology.. 2023 June 41 Suppl 2 :33-35. Epub 1900 01 01.

Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.

Upshaw JN, Nelson J, Rodday AM, Kumar AJ, Klein AK, Konstam MA, Wong JB, Jaffe IZ, Ky B, Friedberg JW, Maurer M, Kent DM, Parsons SK

JAMA cardiology.. 2023 May 18 (5):453-461. Epub 1900 01 01.

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.

Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman J, Strouse CS, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS

Blood.. 2023 April 13141 (15):1888-1893. Epub 1900 01 01.

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.

Rodday AM, Parsons SK, Upshaw JN, Friedberg JW, Gallamini A, Hawkes E, Hodgson D, Johnson P, Link BK, Mou E, Savage KJ, Zinzani PL, Maurer M, Evens AM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 April 1041 (11):2076-2086. Epub 12/10/2022.

Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis.

Torka P, Pederson LD, Knopp MV, Poon D, Zhang J, Kahl BS, Higley HR, Kelloff G, Friedberg JW, Schwartz LH, Wilson WH, Leonard JP, Bartlett NL, Schöder H, Ruppert AS

Cancer medicine. 2023 April 12 (7):8211-8217. Epub 02/17/2023.

ASCO Living Guidelines: The Next Frontier.

Giri VN, Oliver TK, Rumble RB, Friedberg JW, Miller KD, Geisel RL

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 February 1041 (5):955-957. Epub 12/19/2022.

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.

Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 January 1041 (2):336-342. Epub 07/05/2022.

Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy.

Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 January 1041 (2):151-152. Epub 1900 01 01.

Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors.

Ramsey SD, Friedberg JW, Cox JV, Peppercorn JM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 January 141 (1):3-6. Epub 09/02/2022.

Turns 40.

Miller KD, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 January 141 (1):1-2. Epub 11/18/2022.

Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.

Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW

Haematologica.. 2022 November 1107 (11):2732-2736. Epub 11/01/2022.

Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors.

Ramsey SD, Friedberg JW, Cox JV, Peppercorn JM

JCO oncology practice.. 2022 November 18 (11):733-735. Epub 09/02/2022.

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study.

Flowers C, Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn?ný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Salles G

Clinical lymphoma, myeloma & leukemia.. 2022 October 22 Suppl 2 :S358-S359. Epub 1900 01 01.

EXABS-196-ABCL Has R-CHOP Really Been Replaced as Initial Therapy of Diffuse Large B-cell Lymphoma (DLBCL)?

Friedberg JW

Clinical lymphoma, myeloma & leukemia.. 2022 October 22 Suppl 2 :S89-S90. Epub 1900 01 01.

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman A, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles GA, San-Miguel JF, Seymour JF, Treon SP, Vose J, Zucca E, Advani R, Ansell SM, Au WY, Barrionuevo C, Bergsagel PL, Chan WC, Cohen JI, Davies AJ, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar SK, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, López-Guillermo A, Mateos MV, Macintyre EA, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris MA, Pro B, Rajkumar SVV, Rosen ST, Sander B, Sehn LH, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD

Blood.. 2022 September 15140 (11):1229-1253. Epub 1900 01 01.

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.

Luan D, Fatola T, Toure A, Flowers CR, Link BK, Friedberg JW, Cohen JB, Kahl BS, Lossos IS, Nastoupil LJ, Maurer MJ, Cerhan JR, Martin P

Blood advances.. 2022 August 96 (15):4413-4423. Epub 1900 01 01.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

Ansell SM, Radford J, Connors JM, D?ugosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ,

The New England journal of medicine.. 2022 July 28387 (4):310-320. Epub 07/13/2022.

Introducing Clinical Trial Updates.

Miller KD, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 May 2040 (15):1599-1600. Epub 04/14/2022.

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.

Harkins RA, Patel S, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum K, Cashen AF, Casulo C, Friedberg JW, Johnston P, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan P, Westin JR, Koff JL, Flowers CR

Blood advances.. 2022 May 106 (9):2745-2756. Epub 1900 01 01.

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.

Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS

Blood advances.. 2022 April 126 (7):2035-2044. Epub 1900 01 01.

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.

Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM

Journal of geriatric oncology.. 2022 March 13 (2):258-264. Epub 10/20/2021.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn?ný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G

The New England journal of medicine.. 2022 January 27386 (4):351-363. Epub 12/14/2021.

ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS

Bone marrow transplantation.. 2021 December 56 (12):2911-2921. Epub 08/20/2021.

Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.

Kumar AJ, Nelson J, Rodday AM, Evens AM, Friedberg JW, Wildes TM, Parsons SK

Journal of geriatric oncology.. 2021 November 12 (8):1233-1239. Epub 07/28/2021.

Classical Hodgkin lymphoma.

Brice P, de Kerviler E, Friedberg JW

Lancet.. 2021 October 23398 (10310):1518-1527. Epub 01/22/2021.

Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma.

Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK

JAMA network open.. 2021 October 14 (10):e2128373. Epub 10/01/2021.

An Oncology Renaissance.

Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 September 139 (25):2737-2738. Epub 07/16/2021.

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.

Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS

Transplantation and cellular therapy.. 2021 September 27 (9):720-728. Epub 1900 01 01.

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.

Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 July 1039 (20):2257-2265. Epub 04/28/2021.

Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.

Zent CS, Brady MT, Delage C, Strawderman M, Laniewski N, Contant PN, Kanagaiah P, Sangster MY, Barr PM, Chu CC, Topham DJ, Friedberg JW

Leukemia.. 2021 June 35 (6):1788-1791. Epub 10/30/2020.

A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).

Rummel MJ, Janssens A, MacDonald D, Keating MM, Zaucha JM, Davis J, Lasher J, Babanrao Pisal C, Izquierdo M, Friedberg JW

British journal of haematology.. 2021 June 193 (6):1123-1133. Epub 05/10/2021.

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.

Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, Wade JL, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, Little RF, Leonard JP, Friedberg JW, Kostakoglu L, Kahl BS, Witzig TE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 April 2039 (12):1329-1338. Epub 02/08/2021.

Safety and efficacy of navitoclax, a BCL-2 and BCL-X inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.

de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, Hayslip J, Pesko J, Wilson WH

Leukemia & lymphoma.. 2021 April 62 (4):810-818. Epub 11/25/2020.

Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.

Reagan PM, Friedberg JW

Future oncology.. 2021 April 17 (11):1269-1283. Epub 01/15/2021.

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.

Hutchings M, Radford J, Ansell SM, Illés Á, Sureda A, Connors JM, Sýkorová A, Shibayama H, Abramson JS, Chua NS, Friedberg JW, Ko?en J, LaCasce AS, Molina L, Engley G, Fenton K, Jolin H, Liu R, Gautam A, Gallamini A

Hematological oncology.. 2021 April 39 (2):185-195. Epub 02/16/2021.

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.

Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM

Leukemia & lymphoma.. 2021 March 62 (3):598-605. Epub 10/25/2020.

Immunotherapy for Hematologic Malignancies.

Craddock C, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 February 1039 (5):343-345. Epub 01/12/2021.

Reply to E. Hawkes et al.

Persky DO, Smith SM, LeBlanc ML, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 December 1038 (35):4222-4223. Epub 10/26/2020.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.

Neelapu SS, Adkins S, Ansell SM, Brody J, Cairo MS, Friedberg JW, Kline JP, Levy R, Porter DL, van Besien K, Werner M, Bishop MR

Journal for immunotherapy of cancer.. 2020 December 8 (2)Epub 1900 01 01.

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.

Ha CS, LeBlanc M, Schöder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, Friedberg JW

Leukemia & lymphoma.. 2020 October 61 (10):2442-2447. Epub 05/26/2020.

Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma.

Rodgers TD, Friedberg JW

Hematology/oncology clinics of North America.. 2020 October 34 (5):983-996. Epub 08/05/2020.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 September 1038 (26):3003-3011. Epub 07/13/2020.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 August 138 (22):2519-2529. Epub 05/26/2020.

Toward a Cure for Follicular Lymphoma.

Friedberg JW

Hematology/oncology clinics of North America.. 2020 August 34 (4):xiii-xiv. Epub 05/20/2020.

Optimizing the Use of Oral Therapy in Lymphoma.

Friedberg JW

Clinical advances in hematology & oncology : H&O.. 2020 August 18 (8):454-456. Epub 1900 01 01.

First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study.

Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK

British journal of haematology.. 2020 July 190 (2):222-235. Epub 02/23/2020.

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.

Schöder H, Polley MY, Knopp MV, Hall NC, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz A, Cheson BD, Wagner-Johnston ND, Kahl B, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL

Blood.. 2020 June 18135 (25):2224-2234. Epub 1900 01 01.

Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.

Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM

British journal of haematology.. 2020 February 188 (4):e33-e36. Epub 12/17/2019.

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM

Leukemia & lymphoma.. 2019 December 60 (14):3569-3572. Epub 07/08/2019.

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM

Blood advances.. 2019 October 223 (20):3132-3135. Epub 1900 01 01.

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.

Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW

Blood.. 2019 October 10134 (15):1238-1246. Epub 1900 01 01.

Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs.

Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, Nastoupil LJ

Leukemia & lymphoma.. 2019 October 60 (10):2356-2364. Epub 06/04/2019.

Integrating Assessment of Sarcopenia into Decision-making for Allogeneic Hematopoietic Cell Transplantation: Ready for Prime Time?

Loh KP, Dunne RF, Friedberg JW, Mohile SG

Journal of the National Cancer Institute.. 2019 August 1111 (8):757-759. Epub 1900 01 01.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ

Leukemia & lymphoma.. 2019 August 60 (8):1934-1941. Epub 01/10/2019.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 July 2037 (21):1790-1799. Epub 04/02/2019.

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.

Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M

JAMA oncology.. 2019 May 15 (5):715-722. Epub 1900 01 01.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW

Blood.. 2019 April 18133 (16):1762-1765. Epub 02/05/2019.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2019 March 1525 (6):1718-1726. Epub 01/07/2019.

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.

Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW

British journal of haematology.. 2019 February 184 (4):660-663. Epub 04/02/2018.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M

Blood.. 2019 January 3133 (1):81-93. Epub 11/16/2018.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM

Clinical lymphoma, myeloma & leukemia.. 2019 January 19 (1):41-47. Epub 10/13/2018.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2018 December 1524 (24):6150-6159. Epub 08/06/2018.

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM

Clinical lymphoma, myeloma & leukemia.. 2018 December 18 (12):781-787. Epub 08/29/2018.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH

The Lancet. Haematology.. 2018 December 5 (12):e609-e617. Epub 1900 01 01.

Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen RS, Candia AF, Coffman RL, Levy R

Cancer discovery.. 2018 October 8 (10):1258-1269. Epub 08/28/2018.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL

Blood.. 2018 September 6132 (10):1013-1021. Epub 07/26/2018.

Burkitt lymphoma- a rare but challenging lymphoma.

Casulo C, Friedberg JW

Best practice & research. Clinical haematology.. 2018 September 31 (3):279-284. Epub 07/23/2018.

Progress in Advanced-Stage Follicular Lymphoma.

Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2018 August 1036 (23):2363-2365. Epub 06/01/2018.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.

Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW

American journal of hematology.. 2018 August 93 (4):486-493. Epub 01/25/2018.

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2018 June 24 (6):1163-1171. Epub 12/11/2017.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2018 April 24 (4):700-707. Epub 12/28/2017.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.

Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW

Haematologica.. 2018 April 103 (4):e151-e153. Epub 02/22/2018.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2018 March 136 (7):697-703. Epub 01/22/2018.

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW

The Lancet. Haematology.. 2018 March 5 (3):e102-e108. Epub 01/26/2018.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM

Cancer.. 2018 January 1124 (1):136-144. Epub 09/13/2017.

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ?60 years with HL.

Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ, Olsen G, Chen R, Fong A, Wang Y, Yasenchak CA

Blood.. 2017 December 28130 (26):2829-2837. Epub 10/16/2017.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY

The New England journal of medicine.. 2017 December 28377 (26):2531-2544. Epub 12/10/2017.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM

Blood advances.. 2017 December 121 (26):2600-2609. Epub 12/11/2017.

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.

Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K, Gribben JG, Friedberg JW, Seymour JF, Cavalli F, Zucca E

Hematological oncology.. 2017 December 35 (4):397-407. Epub 04/04/2017.

State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.

Xi D, Bao T, Chen Q, Chen S, Cheng YC, Cullen J, Frank DA, Friedberg JW, Kronish I, Lee JE, Levine M, Li P, Li S, Lu W, Mao JJ, O'Keefe S, Rubinstein L, Shah MA, Standish L, Paller CJ, Chu E

Journal of the National Cancer Institute. Monographs.. 2017 November 12017 (52)Epub 1900 01 01.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2017 November 23 (11):1826-1838. Epub 08/07/2017.

Unmet needs in the first-line treatment of follicular lymphoma.

Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR

Annals of oncology : official journal of the European Society for Medical Oncology. 2017 September 128 (9):2094-2106. Epub 1900 01 01.

How I treat double-hit lymphoma.

Friedberg JW

Blood.. 2017 August 3130 (5):590-596. Epub 06/09/2017.

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP

British journal of haematology.. 2017 July 178 (2):250-256. Epub 04/17/2017.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2017 June 135 (16):1803-1813. Epub 03/14/2017.

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW

Blood.. 2017 June 1129 (22):3037-3039. Epub 03/21/2017.

Chemotherapy free treatment of indolent lymphoma.

Casulo C, Friedberg JW

Hematological oncology.. 2017 June 35 Suppl 1 :20-24. Epub 1900 01 01.

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.

Reagan PM, Friedberg JW

Oncology.. 2017 May 1531 (5):402-11. Epub 1900 01 01.

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.

Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD, Dawson KL, Reid E

Leukemia & lymphoma.. 2017 April 58 (4):809-815. Epub 08/12/2016.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL

Journal of the National Cancer Institute.. 2017 April 109 (4)Epub 12/31/2016.

Introduction to Genomics in Hematologic Malignancy.

Ebert BL, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2017 March 2035 (9):927-928. Epub 02/13/2017.

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.

Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW

British journal of haematology.. 2017 March 176 (5):759-769. Epub 12/19/2016.

Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.

Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C

Clinical lymphoma, myeloma & leukemia.. 2017 March 17 (3):145-151. Epub 11/23/2016.

Recommendations for Clinical Trial Development in Follicular Lymphoma.

Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM

Journal of the National Cancer Institute.. 2017 March 109 (3)Epub 12/31/2016.

Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.

Danilov AV, Li H, Press OW, Shapira I, Swinnen LJ, Noy A, Reid E, Smith SM, Friedberg JW

Leukemia & lymphoma.. 2017 February 58 (2):461-465. Epub 07/07/2016.

T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.

Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, Kahl BS, Little RF, Pinter-Brown L, Advani R, Horwitz S

Journal of the National Cancer Institute.. 2017 February 109 (2)Epub 12/31/2016.

Reply to H.J.A. Adams et al and E.A. Hawkes et al.

Press OW, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2017 January 2035 (3):373. Epub 10/28/2016.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR

Journal of the National Cancer Institute.. 2017 January 109 (1)Epub 12/31/2016.

General Biomarker Recommendations for Lymphoma.

Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M, Baizer L, Fu K, Hsi E, Chan JW, McShane L, Leonard JP, Kahl BS, Little RF, Friedberg JW, Kostakoglu L

Journal of the National Cancer Institute.. 2016 December 108 (12)Epub 12/16/2016.

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM

Journal of the National Cancer Institute.. 2016 December 108 (12)Epub 12/16/2016.

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.

Reid RM, Baran A, Friedberg JW, Phillips GL, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA

Cancer medicine. 2016 November 5 (11):3059-3067. Epub 10/03/2016.

Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse.

Dhakal S, Bates JE, Casulo C, Friedberg JW, Becker MW, Liesveld JL, Constine LS

International journal of radiation oncology, biology, physics.. 2016 October 196 (2):372-378. Epub 05/27/2016.

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.

Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO

Leukemia & lymphoma.. 2016 October 57 (10):2359-69. Epub 01/12/2016.

Evaluation of the ProPublica Surgeon Scorecard "Adjusted Complication Rate" Measure Specifications.

Ban KA, Cohen ME, Ko CY, Friedberg MW, Stulberg JJ, Zhou L, Hall BL, Hoyt DB, Bilimoria KY

Annals of surgery.. 2016 October 264 (4):566-74. Epub 1900 01 01.

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.

Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson MM, Zelenetz AD, Niland J, Friedberg JW, Winter JN

Journal of the National Comprehensive Cancer Network : JNCCN.. 2016 October 14 (10):1274-1281. Epub 1900 01 01.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH

Blood.. 2016 September 15128 (11):1458-64. Epub 07/25/2016.

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 September 134 (25):2997-3004. Epub 07/05/2016.

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.

Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM

British journal of haematology.. 2016 September 174 (5):686-91. Epub 04/13/2016.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.

Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O

Blood.. 2016 August 25128 (8):1112-20. Epub 07/14/2016.

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.

Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR

American journal of hematology.. 2016 August 91 (8):770-5. Epub 05/24/2016.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 June 1034 (17):2020-7. Epub 04/11/2016.

Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma.

Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW

Clinical lymphoma, myeloma & leukemia.. 2016 June 16 (6):322-328.e2. Epub 04/02/2016.

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW

Blood.. 2016 May 19127 (20):2411-5. Epub 03/11/2016.

Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.

Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR

British journal of haematology.. 2016 March 172 (5):724-34. Epub 01/05/2016.

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW

European journal of cancer : official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR).. 2016 February 54 :11-17. Epub 12/18/2015.

Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW

British journal of haematology.. 2016 January 172 (2):208-18. Epub 10/22/2015.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.

Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW

Leukemia & lymphoma.. 2016 57 (3):635-43. Epub 10/12/2015.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV

Journal for immunotherapy of cancer.. 2016 4 :90. Epub 12/20/2016.

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA

Blood.. 2015 December 24126 (26):2798-804. Epub 09/16/2015.

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH

British journal of haematology.. 2015 November 171 (4):530-8. Epub 09/07/2015.

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

Casulo C, Day B, Dawson KL, Zhou X, Flowers CR, Farber CM, Hainsworth JD, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW

Annals of oncology : official journal of the European Society for Medical Oncology. 2015 November 26 (11):2311-7. Epub 09/11/2015.

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 October 2033 (30):3467-74. Epub 08/17/2015.

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells.

Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL

British journal of haematology.. 2015 October 171 (2):205-209. Epub 06/18/2015.

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA

American journal of hematology.. 2015 September 90 (9):778-83. Epub 1900 01 01.

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).

Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, Friedberg JW, Bartlett NL

Blood.. 2015 August 13126 (7):851-7. Epub 06/23/2015.

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 August 1033 (23):2516-22. Epub 06/29/2015.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 July 2033 (21):2399-404. Epub 06/15/2015.

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.

Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR

British journal of haematology.. 2015 July 170 (1):85-95. Epub 04/07/2015.

Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Reagan PM, Friedberg JW

Current treatment options in oncology.. 2015 July 16 (7):32. Epub 1900 01 01.

Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.

Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, Deshaies RJ, Land H, Zhao J

Oncotarget.. 2015 June 206 (17):14796-813. Epub 1900 01 01.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 June 1033 (17):1936-42. Epub 04/20/2015.

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S

Blood.. 2015 May 7125 (19):2915-22. Epub 03/09/2015.

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 May 133 (13):1482-90. Epub 03/30/2015.

Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.

Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR

Leukemia & lymphoma.. 2015 May 56 (5):1295-302. Epub 11/05/2014.

Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.

Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA

Cancer.. 2015 April 1121 (7):1032-9. Epub 12/09/2014.

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.

Friedberg JW

Chinese clinical oncology.. 2015 March 4 (1):9. Epub 1900 01 01.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell S

Blood.. 2015 February 5125 (6):992-8. Epub 11/24/2014.

Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma.

Hutchinson K, Jahangiri S, Calvi LM, Barr P, Friedberg JW, Kelly JL

Leukemia & lymphoma.. 2015 February 56 (2):508-11. Epub 07/15/2014.

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.

Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI

Blood.. 2015 January 8125 (2):236-41. Epub 11/13/2014.

Transformed follicular non-Hodgkin lymphoma.

Casulo C, Burack WR, Friedberg JW

Blood.. 2015 January 1125 (1):40-7. Epub 12/11/2014.

Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

Reagan PM, Friedberg JW

Future oncology.. 2015 11 (10):1543-53. Epub 1900 01 01.

Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.

Friedberg JW

Hematology. 2015 2015 :618-24. Epub 1900 01 01.

End of rituximab maintenance for low-tumor burden follicular lymphoma.

Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 October 132 (28):3093-5. Epub 08/25/2014.

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.

Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA

Leukemia & lymphoma.. 2014 October 55 (10):2328-34. Epub 02/24/2014.

PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.

Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2014 September 1520 (18):4849-60. Epub 07/28/2014.

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.

Casulo C, Vose JM, Ho WY, Kahl B, Brunvand M, Goy A, Kasamon Y, Cheson B, Friedberg JW

Clinical immunology : the official journal of the Clinical Immunology Society.. 2014 September 154 (1):37-46. Epub 06/11/2014.

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

Jahangiri S, Barr P, Friedberg J

Expert opinion on emerging drugs.. 2014 September 19 (3):367-83. Epub 06/24/2014.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM

Blood.. 2014 August 21124 (8):1259-65. Epub 07/11/2014.

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.

Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI

British journal of haematology.. 2014 August 166 (3):382-9. Epub 04/18/2014.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y

The Lancet. Oncology.. 2014 August 15 (9):1019-26. Epub 07/17/2014.

Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project.

Mbulaiteye SM, Morton LM, Sampson JN, Chang ET, Costas L, de Sanjosé S, Lightfoot T, Kelly J, Friedberg JW, Cozen W, Marcos-Gragera R, Slager SL, Birmann BM, Weisenburger DD

Journal of the National Cancer Institute. Monographs.. 2014 August 2014 (48):106-14. Epub 1900 01 01.

Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjosé S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadié M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN

Journal of the National Cancer Institute. Monographs.. 2014 August 2014 (48):130-44. Epub 1900 01 01.

Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.

Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS

Cancer.. 2014 July 1120 (13):1993-9. Epub 04/04/2014.

Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study.

Weeks JC, Uno H, Taback N, Ting G, Cronin A, D'Amico TA, Friedberg JW, Schrag D

Annals of internal medicine.. 2014 July 1161 (1):20-30. Epub 1900 01 01.

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.

Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR

Cancer.. 2014 June 15120 (12):1830-7. Epub 03/25/2014.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN

Blood.. 2014 February 6123 (6):837-42. Epub 11/21/2013.

Treatment of Hodgkin lymphoma: a 50-year perspective.

Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 January 2032 (3):163-8. Epub 1900 01 01.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 January 132 (1):44-50. Epub 09/16/2013.

Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.

Martin P, Byrtek M, Dawson K, Ziemiecki R, Friedberg JW, Cerhan JR, Flowers CR, Link BK

Cancer.. 2013 December 1119 (23):4129-36. Epub 09/04/2013.

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2013 December 119 (23):6624-32. Epub 10/15/2013.

Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.

Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW

British journal of haematology.. 2013 November 163 (4):487-95. Epub 09/20/2013.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI

The New England journal of medicine.. 2013 October 31369 (18):1681-90. Epub 1900 01 01.

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.

Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW

Cancer.. 2013 October 15119 (20):3662-71. Epub 08/06/2013.

Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database.

Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS

Leukemia & lymphoma.. 2013 October 54 (10):2155-62. Epub 02/25/2013.

Management of marginal zone lymphoma.

Reid R, Friedberg JW

Oncology.. 2013 September 27 (9):840, 842, 844. Epub 1900 01 01.

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.

Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW

Leukemia.. 2013 August 27 (8):1769-73. Epub 02/06/2013.

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study.

Vose JM, Friedberg JW, Waller EK, Cheson BD, Juvvigunta V, Fritsch H, Petit C, Munzert G, Younes A

Leukemia & lymphoma.. 2013 April 54 (4):708-13. Epub 10/04/2012.

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2013 February 2031 (6):684-91. Epub 11/26/2012.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR

Annals of oncology : official journal of the European Society for Medical Oncology. 2013 February 24 (2):441-448. Epub 10/05/2012.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR

Annals of oncology : official journal of the European Society for Medical Oncology. 2013 February 24 (2):441-448. Epub 12/04/2019.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2013 January 2031 (3):314-20. Epub 12/10/2012.

Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.

Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR

Cancer.. 2012 October 1118 (19):4842-50. Epub 03/20/2012.

Double-hit diffuse large B-cell lymphoma.

Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 October 130 (28):3439-43. Epub 09/04/2012.

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 September 2030 (27):3368-75. Epub 08/20/2012.

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.

Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA

Cancer.. 2012 June 1118 (11):2944-51. Epub 10/17/2011.

High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.

Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS

Leukemia & lymphoma.. 2012 June 53 (6):1113-6. Epub 02/03/2012.

Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma.

Biswas T, Culakova E, Friedberg JW, Kelly JL, Dhakal S, Liesveld J, Phillips GL, Constine LS

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2012 June 103 (3):367-72. Epub 03/05/2012.

Mantle cell lymphoma.

Friedberg JW

Best practice & research. Clinical haematology.. 2012 June 25 (2):131-2. Epub 05/17/2012.

Novel agents in mantle cell lymphoma.

Noel MS, Friedberg JW, Barr PM

Best practice & research. Clinical haematology.. 2012 June 25 (2):191-200. Epub 04/30/2012.

High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.

Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW

Leukemia & lymphoma.. 2012 May 53 (5):830-5. Epub 12/06/2011.

Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S

Molecular cancer therapeutics.. 2012 May 11 (5):1122-32. Epub 03/12/2012.

Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.

Keller SF, Kelly JL, Sensenig E, Andreozzi J, Oliva J, Rich L, Constine L, Becker M, Phillips G, Liesveld J, Fisher RI, Bernstein SH, Friedberg JW

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2012 April 18 (4):640-7. Epub 08/24/2011.

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW

Blood.. 2012 March 1119 (9):2093-9. Epub 01/10/2012.

Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion.

Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW

Clinical immunology : the official journal of the Clinical Immunology Society.. 2012 March 142 (3):237-42. Epub 01/05/2012.

Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.

Carter SJ, Bernstein SH, Friedberg JW, Barr PM

Leukemia research.. 2011 November 35 (11):e223-4. Epub 08/06/2011.

New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice.

Friedberg JW

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2011 October 117 (19):6112-7. Epub 08/15/2011.

Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S

Molecular cancer therapeutics.. 2011 September 10 (9):1686-97. Epub 07/12/2011.

Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease.

Milner LA, Becker MW, Bernstein SH, Bruckner L, Friedberg JW, Holland GA, Ifthikharuddin JJ, Liesveld JL, Mathes EJ, Menchel HL, Mullen CA, Sasson T, Phillips GL

American journal of hematology.. 2011 August 86 (8):712-4. Epub 05/31/2011.

A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.

Phillips GL, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2011 July 17 (7):1033-42. Epub 11/11/2010.

Getting to the heart of the problem in treating diffuse large B-cell lymphoma.

Barr PM, Friedberg JW

Leukemia & lymphoma.. 2011 July 52 (7):1166-7. Epub 05/25/2011.

Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Cheson BD, Rai KR, Friedberg JW

Clinical advances in hematology & oncology : H&O.. 2011 July 9 (7 Suppl 15):1-11. Epub 1900 01 01.

Hodgkin lymphoma: answers take time!

Friedberg JW

Blood.. 2011 May 19117 (20):5274-6. Epub 1900 01 01.

ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II.

Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ

Journal of the American College of Radiology : JACR.. 2011 May 8 (5):302-8. Epub 1900 01 01.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP

Blood.. 2011 March 10117 (10):2807-12. Epub 01/14/2011.

CLL microenvironment: macro important.

Friedberg JW

Blood.. 2011 January 13117 (2):377-8. Epub 1900 01 01.

Rituximab maintenance in follicular lymphoma: PRIMA.

Friedberg JW

Lancet.. 2011 January 1377 (9759):4-6. Epub 12/20/2010.

Relapsed/refractory diffuse large B-cell lymphoma.

Friedberg JW

Hematology. 2011 2011 :498-505. Epub 1900 01 01.

Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L

Clinical lymphoma, myeloma & leukemia.. 2010 December 10 (6):452-7. Epub 1900 01 01.

A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults.

Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG

Cancer causes & control : CCC.. 2010 August 21 (8):1265-75. Epub 04/07/2010.

Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?

Dougherty DW, Friedberg JW

Current hematologic malignancy reports.. 2010 July 5 (3):148-56. Epub 1900 01 01.

PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection.

Burack WR, Laughlin TS, Friedberg JW, Spence JM, Rothberg PG

American journal of clinical pathology.. 2010 July 134 (1):104-11. Epub 1900 01 01.

Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.

Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS

International journal of radiation oncology, biology, physics.. 2010 May 177 (1):79-85. Epub 08/03/2009.

Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.

Kahl BS, Cheson BD, Friedberg JW

Clinical advances in hematology & oncology : H&O.. 2010 May 8 (5):1-16. Epub 1900 01 01.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA

Blood.. 2010 April 1115 (13):2578-85. Epub 11/17/2009.

PET positive, PET negative, or PET peeve?

Friedberg JW

Blood.. 2010 January 28115 (4):752-3. Epub 1900 01 01.

ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma.

Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ

Current problems in cancer.. 2010 34 (3):211-27. Epub 1900 01 01.

Vitamin D and non-Hodgkin lymphoma risk in adults: a review.

Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG

Cancer investigation.. 2009 November 27 (9):942-51. Epub 1900 01 01.

Symptomatic intracardiac diffuse large B-cell lymphoma.

Ban-Hoefen M, Bernstein SH, Bisognano JD, Pryor JG, Friedberg JW

American journal of hematology.. 2009 October 84 (10):683-5. Epub 1900 01 01.

Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma.

Dhakal S, Biswas T, Liesveld JL, Friedberg JW, Phillips GL, Constine LS

International journal of radiation oncology, biology, physics.. 2009 September 175 (1):188-92. Epub 02/26/2009.

Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.

Friedberg JW

Leukemia & lymphoma.. 2009 September 50 (9):1399-400. Epub 1900 01 01.

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS

British journal of haematology.. 2009 August 146 (3):282-91. Epub 06/10/2009.

Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW

Clinical lymphoma & myeloma. 2009 August 9 (4):307-10. Epub 1900 01 01.

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.

Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS

British journal of haematology.. 2009 June 145 (6):741-8. Epub 03/30/2009.

Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapies.

Sud R, Friedberg JW

Oncology.. 2009 June 23 (7):615-6, 619. Epub 1900 01 01.

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.

Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ, Bankert RB, Bernstein SH

Blood.. 2009 April 16113 (16):3809-12. Epub 02/04/2009.

Salvage therapy in Hodgkin's lymphoma.

Mendler JH, Friedberg JW

The oncologist.. 2009 April 14 (4):425-32. Epub 04/02/2009.

Follicular lymphoma in the United States: first report of the national LymphoCare study.

Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2009 March 1027 (8):1202-8. Epub 02/09/2009.

The emerging role of bendamustine in follicular lymphoma.

Friedberg JW

Leukemia & lymphoma.. 2009 March 50 (3):317-8. Epub 1900 01 01.

Seeking wisdom from the Seer.

McLaughlin P, Friedberg JW

Leukemia & lymphoma.. 2009 February 50 (2):145-7. Epub 1900 01 01.

Outcomes of patients with Burkitt lymphoma older than age 40 treated with aggressive chemotherapeutic regimens

Toothaker SR, Kelly J, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead , Thomas D, van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW.

Clinical Lymphoma and Myeloma. 2009; in press.

Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database.

Kho ME, Lepisto EM, Niland JC, Friedberg JW, Lacasce AS, Weeks JC

Cancer.. 2008 December 1113 (11):3209-12. Epub 1900 01 01.

Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab.

Sud R, Friedberg JW

Haematologica.. 2008 December 93 (12):1776-80. Epub 1900 01 01.

Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.

LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, Czuczman MS, Millenson MM, Zelenetz AD, Weeks JC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2008 November 126 (31):5107-12. Epub 09/02/2008.

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW

Annals of oncology : official journal of the European Society for Medical Oncology. 2008 October 19 (10):1759-64. Epub 05/25/2008.

Diffuse large B-cell lymphoma.

Friedberg JW, Fisher RI

Hematology/oncology clinics of North America.. 2008 October 22 (5):941-52, ix. Epub 1900 01 01.

Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

Sikder MA, Friedberg JW

Current hematologic malignancy reports.. 2008 October 3 (4):187-93. Epub 1900 01 01.

Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

Sikder MA, Friedberg JW

Current oncology reports.. 2008 September 10 (5):420-6. Epub 1900 01 01.

Treatment of follicular non-Hodgkin's lymphoma: the old and the new.

Friedberg JW

Seminars in hematology.. 2008 July 45 (3 Suppl 2):S2-6. Epub 1900 01 01.

Bak to death with chemotherapy.

Friedberg JW

Blood.. 2008 June 1111 (11):5263-4. Epub 1900 01 01.

Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.

Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW

Cancer investigation.. 2008 May 26 (4):431-3. Epub 1900 01 01.

Monoclonal antibodies in lymphoma: the first decade.

Link BK, Friedberg JW

Seminars in hematology.. 2008 April 45 (2):71-4. Epub 1900 01 01.

Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.

Schaefer-Cutillo J, Friedberg JW

Seminars in hematology.. 2008 April 45 (2):110-7. Epub 1900 01 01.

Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.

Friedberg JW

Haematologica.. 2008 March 93 (3):336-8. Epub 1900 01 01.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2008 January 1026 (2):204-10. Epub 1900 01 01.

Bendamustine in patients with rituximab-refractory and alkylator-refractory, indolent non-Hodgkin's lymphoma: results from a phase I multicenter, single-agent study.

Friedberg JW, Cohen P, Chen L, Robinson K, Forero-Torres A, LaCasce A, Fayad L, Bessudo A, Camacho E, Williams M, van der Jagt R, Oliver J, Loh E, Cheson BD:.

Jounal of Clinical Oncology. 2008; 26: 204-10.

Targeting the follicular lymphoma microenvironment through blockade of TNF-alpha with etanercept.

Friedberg JW, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher DC, Szot A, Van den Abbeele AD, Freedman AS.

Leukemia and Lymphoma. 2008; 49: 902-09.

Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.

Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW.

Cancer Investigation. 2008; 26: 431-3.

Bortezomib and gemcitabine in relapsed or refractory Hodgkin lymphoma.

Mendler J, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW.

Annual Oncology. 2008; 19: 1759-64.

Comparison of Referring and Final Pathology for Non-Hodgkin's Lymphoma Patients in the National Comprehensive Cancer Network (NCCN)

LaCasce AS, Kho ME, Friedberg JW, Niland J, Abel G, Rodriguez MA, Czuczman M, Millenson M, Weeks J.

Journal of Clinical Oncology. 2008; 26: 5107-12.

Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-institutional outcomes database.

Kho ME, Lepisto E, Niland JC, Friedberg JW, LaCasce AS, Weeks JC.

Cancer. 2008; 113: 3209-12.

CNS events in patients with aggressive non Hodgkin's lymphoma: the role of CNS prophylaxis.

Bernstein SH, Unger J, LeBlanc M, Friedberg JW, Miller T, Fisher RI.

Journal of Clinical Oncology. 2008; in press.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker A, Komrokji R, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg JW, Oliva J, Phillips G, Liesveld J, Abboud CA.

Leukemia Research. 2008; 32: 1830-6.

Follicular lymphoma in the United States: First report of the National LymphoCare Study.

Friedberg JW, Taylor MD, Cerhan JR, Flowers C, Dillon H, Farber CM, Rogers E, Hainsworth J, Wong EK, Vose JM, Zelenetz AD, Link BK.

Journal of Clinical Oncology. 2008; : in press.

Symptomatic Intracardiac Diffuse large B-cell lymphoma

Ban-Hoefen M, Bernstein S, Bisognano JD, Pryor JG, Friedberg JW.

American Journal of Hematology. 2008; : in press.

Patterns and Timing of initial relapse in patients transplanted for Hodgkin lymphoma.

Dhakal S, Biswas T, Liesveld J, Friedberg JW, Phillips G, Constine LS.

International Journal of Radiation Oncology,Biology,Physics. 2008; in press.

Burkitt lymphoma in adults.

Perkins AS, Friedberg JW

Hematology. 2008 :341-8. Epub 1900 01 01.

Combination treatment approaches and novel therapies for lymphoma.

Leonard JP, Friedberg JW, Hagemeister FB, Levine AM

Clinical advances in hematology & oncology : H&O.. 2007 August 5 (8 Suppl 12):4-20; quiz 1 p following 20. Epub 1900 01 01.

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.

Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A

Annals of oncology : official journal of the European Society for Medical Oncology. 2007 July 18 (7):1216-23. Epub 04/29/2007.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP,

Annals of oncology : official journal of the European Society for Medical Oncology. 2007 June 18 (6):1071-9. Epub 04/10/2007.

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I

Clinical immunology : the official journal of the Clinical Immunology Society.. 2007 February 122 (2):139-45. Epub 09/27/2006.

Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.

Schaefer-Cutillo J, Friedberg JW, Fisher RI

Oncology.. 2007 February 21 (2):203-12; discussion 214, 217, 221. Epub 1900 01 01.

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

Anolik J, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner ECB, Fisher RI, Sanz I.

Clinical Immunology. 2007; 122: 139-45.

A Phase I/II study of galiximab in combination with rituximab for relapsed or refractory follicular lymphoma

Leonard JP, Friedberg JW*, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A.

Annual Oncology. 2007; 18: 1216-23.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma

Bartlett, NL, Niedzwiecki, D, Johnson, JL, Friedberg, JW, Johnson KB, van Besien K, Zelenetz AD, Cheson, BD, Canellos GP.

Annual Oncology. 2007; 18: 1071-9.

Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma.

Friedberg JW

Haematologica.. 2006 November 91 (11):1453-5. Epub 1900 01 01.

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.

Friedberg JW, Freedman AS

Current treatment options in oncology.. 2006 July 7 (4):276-84. Epub 1900 01 01.

Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience.

Vargas RL, Fallone E, Felgar RE, Friedberg JW, Arbini AA, Andersen AA, Rothberg PG

Leukemia research.. 2006 May 30 (5):547-51. Epub 10/24/2005.

Rituximab for early-stage diffuse large-B-cell lymphoma.

Friedberg JW

The Lancet. Oncology.. 2006 May 7 (5):357-9. Epub 1900 01 01.

Diffuse large B-cell NHL.

Friedberg JW, Fisher RI

Cancer treatment and research.. 2006 131 :121-40. Epub 1900 01 01.

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2005 April 123 (10):2208-14. Epub 03/07/2005.

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS

Blood.. 2005 January 15105 (2):489-95. Epub 09/09/2004.

Update on mantle cell lymphoma and diffuse large B-cell non-Hodgkin's lymphoma.

Fisher RI, Friedberg JW.

Lymphoma Annual Update 2005; Clinical Care Options. 2005; .

Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy.

Friedberg JW

Hematology. 2005 :329-34. Epub 1900 01 01.

Radioimmunotherapy for non-Hodgkin's lymphoma.

Friedberg JW

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2004 December 110 (23):7789-91. Epub 1900 01 01.

Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.

Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH

Seminars in oncology.. 2004 December 31 (6 Suppl 18):59-61. Epub 1900 01 01.

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2004 November 122 (21):4302-11. Epub 09/20/2004.

Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.

Friedberg JW

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2004 August 1510 (16):5297-8. Epub 1900 01 01.

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.

Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG, Fisher DC, Freedman AS, Takvorian T, Jurgens R, Battle TE, Frank DA

Leukemia research.. 2004 February 28 (2):139-47. Epub 1900 01 01.

Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.

Friedberg JW, Fisher RI

Expert review of anticancer therapy.. 2004 February 4 (1):18-26. Epub 1900 01 01.

Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.

Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS

Leukemia & lymphoma.. 2004 February 45 (2):315-20. Epub 1900 01 01.

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.

Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD

Leukemia & lymphoma.. 2004 January 45 (1):85-92. Epub 1900 01 01.

Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.

Friedberg JW, Fisher RI.

Expert Rev Anticancer Therapy. 2004; 4: 18-26.

Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma.

Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H, Fisher DC, Gribben JG, Spitzer T, Freedman AS

Bone marrow transplantation.. 2003 October 32 (7):681-6. Epub 1900 01 01.

Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.

Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP

Cancer.. 2003 September 198 (5):978-82. Epub 1900 01 01.

Hodgkin's Disease

Friedberg JW, Aster J, and Canellos GP.;.

Blood: Principles and Practice of Hematalogy. 2003; .

PET scans in the staging of lymphoma: current status.

Friedberg JW, Chengazi V

The oncologist.. 2003 8 (5):438-47. Epub 1900 01 01.

Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM

Blood.. 2002 September 15100 (6):1989-96. Epub 1900 01 01.

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.

Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS

British journal of haematology.. 2002 June 117 (4):828-34. Epub 1900 01 01.

Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.

Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2002 April 1520 (8):2101-8. Epub 1900 01 01.

Breast lymphoma associated with breast implants: two case-reports and a review of the literature.

Gaudet G, Friedberg JW, Weng A, Pinkus GS, Freedman AS

Leukemia & lymphoma.. 2002 January 43 (1):115-9. Epub 1900 01 01.

Staging and pretreatment evaluation of Hodgkin's disease.

Friedberg JW and DiPiro PJ;.

Atlas of Clinical Oncology, Malignant lymphomas, Malignant Grossbard. 2002; .

Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.

Webb IJ, Friedberg W, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H, Houde H, Monroy R, Schmittling R, Freedman AS

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2002 8 (8):429-34. Epub 1900 01 01.

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.

Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2002 8 (11):601-7. Epub 1900 01 01.

The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma.

Friedberg JW, Neuberg D, Monson E, Jallow H, Nadler LM, Freedman AS

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2001 7 (8):446-53. Epub 1900 01 01.

High-dose therapy for follicular lymphoma.

Freedman A, Friedberg JW, Gribben J

Oncology.. 2000 March 14 (3):321-6, 329; discussion 330-2, 338. Epub 1900 01 01.

Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma.

Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD

Cancer.. 1999 October 1586 (8):1621-7. Epub 1900 01 01.

Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1999 October 17 (10):3128-35. Epub 1900 01 01.

High-dose therapy and stem cell transplantation in follicular lymphoma.

Friedberg JW, Freedman AS

Annals of hematology.. 1999 May 78 (5):203-11. Epub 1900 01 01.

Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.

Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Jallow H, Kuhlman C, Ritz J, Freedman AS

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 1999 5 (4):262-8. Epub 1900 01 01.

Discontinuing antidepressant treatment in major depression.

Viguera AC, Baldessarini RJ, Friedberg J

Harvard review of psychiatry.. 1998 5 (6):293-306. Epub 1900 01 01.

Fatal phenformin-associated lactic acidosis.

Rosand J, Friedberg JW, Yang JM

Annals of internal medicine.. 1997 July 15127 (2):170. Epub 1900 01 01.

Clozapine-caused eosinophilic colitis.

Friedberg JW, Frankenburg FR, Burk J, Johnson W

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.. 1995 June 7 (2):97-8. Epub 1900 01 01.

High risk of eosinophilia in women treated with clozapine.

Banov MD, Tohen M, Friedberg J

The Journal of clinical psychiatry.. 1993 December 54 (12):466-9. Epub 1900 01 01.

From municipal hospital to medical center: Milwaukee County General Hospital, 1965-1980.

Friedberg JW

Wisconsin medical journal.. 1992 September 91 (9):547-9. Epub 1900 01 01.

Epidemiology of second malignancies following lymphoma therapy and screening recommendations.

Friedberg JW, Ng A;.

In Press.

Antibody and immunomodulatory agents in treatment of indolent NHL.

Friedberg JW, Freedman AS.

In Press. .

Books

Evidence-based Hematology (2008)

Chapter: Lymphocyte-predominant Hodgkin's lymphoma. Evidence-based Hematology

Authors: McMahon B, Friedberg JW

Publisher: Evidence based Hematology 2008

Seminars in Hematology (2008)

Chapter: Monoclonal antibodies in lymphoma: the first decade.

Authors: Link BK and Friedberg JW

Publisher: Seminars in Hematology 2008

Seminars in Hematology (2008)

Chapter: Non-myeloablative radioimmunotherapy for lymphoma.

Authors: Schaefer-Cutillo J., Friedberg JW

Publisher: Seminars in Hematology 2008

Current Oncology Reports (2008)

Chapter: Beyond rituximab: the future of monoclonal antibody in B-cell non-Hodgkin's lymphoma.

Authors: Sikder M, Friedberg JW:

Publisher: Current Oncology Reports 2008

Cancer, Principles & Practice of Oncology 8th edition (2008)

Chapter: : Non-Hodgkin's lymphomas

Authors: Friedberg JW, Mauch PM, Rimsza LM, Fisher RI

Publisher: Lippincott Williams & Wilkins 2008

Seminars in Hematology (2008)

Chapter: Treatment of follicular non-Hodgkin's lymphoma: the old and the new.

Authors: Friedberg JW

Publisher: Seminars in Hematology 2008

Hematology/Oncology Clinics of North America (2008)

Chapter: Diffuse Large B cell lymphoma

Authors: Friedberg JW, Fisher RI

Publisher: Hematology/Oncology Clinics of North America 2008

Oncology (2007)

Chapter: Novel Concepts in Radioimmunotherapy for Non-Hodgkin's Lymphoma

Authors: Schaefer-Cutillo J, Friedberg JW, Fisher RI

Publisher: Oncology 2007

Cancer Investigation (2007)

Chapter: Role of Bortezomib in the treatment of lymphoma.

Authors: Barr P, Fisher RI, Friedberg JW

Publisher: Cancer Investigation 2007

Clinical Advancements in Hematology and Oncology 5 (2007)

Chapter: Combination treatment approaches and novel therapies for lymphoma.

Authors: Leonard JP, Friedberg JW, Hagameister FB, Levine AM

Publisher: Clinical Advancements in Hematology and Oncology 5 2007

The Lymphomas (2006)

Chapter: Pst-Transplant Lympoproliferative Disease

Authors: Friedberg JW, Swinnen LJ

Publisher: Elsevier 2006

The Lymphomas (2006)

Chapter: Large-cell lymphoma, nodal, splenic

Authors: Friedberg JW, Fisher RI

Publisher: Elsvier 2006

The Lymphomas (2006)

Chapter: Hodgkin lymphoma, Diagnosis

Authors: Friedberg JW

Publisher: Elsvier 2006

Clinical Malignant Hematology (2006)

Chapter: Epidemiology of second malignancies following lymphoma therapy and screening recommendations.

Authors: Friedberg JW, Ng, A

Publisher: McGraw-Hill 2006

Hodgkin and non-Hodgkin lymphoma (2006)

Chapter: "Diffuse Large B-cell Lymphoma"

Authors: Friedberg JW, Fisher RI

Publisher: Springer, NY, USA, 2006

Current Treatment Options Oncology (2006)

Chapter: Antibody and immunomodulatory agents in treatment of indolent NHL.

Authors: Friedberg JW, Freedman AS

Publisher: Current Treatment options Oncology 2006

Cancer Treatment Research (2006)

Chapter: Diffuse Large B Cell NHL

Authors: Friedberg JW, Fisher RI

Publisher: Cancer Treatment Research 2006

Cancer, Principles & Practice of Oncology (2005)

Chapter: Non-Hodgkin's Lymphoma

Authors: Fisher RI, Mauch PM, Harris NL, Friedberg JW

Publisher: Lippincott Williams & Wilkins, Philadelphia, PA 2005

Hematology 2005 (2005)

Chapter: Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy.

Authors: Friedberg JW

Publisher: American Society of Hematology Education Program Book 2005

Lymphoma Annual Update 2005 (2005)

Chapter: Update on mantle cell lymphoma and diffuse large B-cell non-Hodgkin's lymphoma.

Authors: Fisher RI, Friedberg JW

Publisher: at http://clinicaloptions.com/lymphoma2005 2005

American Society of Hematology Education (2005)

Chapter: Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy.

Authors: Friedberg JW

Publisher: American Society of Hematology Education Program Book 2005

Non-Hodgkin's Lymphoma (2004)

Chapter: Follicular lymphoma

Authors: Freedman AS, Friedberg JW

Publisher: Lippincott, Williams and Wilkins, Philadelphia, PA 2004

Blood: Principles and Practice of Hematology (2003)

Chapter: Hodgkin's Disease

Authors: Friedberg JW, Aster J, and Canellos GP

Publisher: Lippincott, Williams and Wilkins, Philadelphia, PA 2003

Clinical Bone Marrow and Stem Cell Transplantation (2003)

Chapter: Myelodysplasia after autologous stem cell transplantation.

Authors: Friedberg JW

Publisher: Cambridge University Press 2003

Clinical Practice of Hematology and Oncology (2003)

Chapter: Cancer and the Immunocompromised Host.

Authors: Scadden DT and Friedberg JW

Publisher: WB Saunders Company, Philadelphia, PA 2003

Atlas of Clinical Oncology, Malignant lymphomas, ML Grossband (2002)

Chapter: Staging and pretreatment evaluation of Hodgkin's disease.

Authors: Friedberg JW and Dipiro PJ

Publisher: B C Decker Inc., Hamilton, London 2002

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

5.0 stars

During this visit, did this provider show respect for what you had to say?

5.0 stars

During this visit did this provider give you easy to understand information about these health questions or concerns?

5.0 stars

During this visit, did this provider listen carefully to you?

5.0 stars

During this visit, did this provider explain things in a way that was easy to understand?

5.0 stars

Patient Comments

I have recommended the practice

Aug 10, 2024

5.0 stars

They are the best team I have ever encountered.

Jul 07, 2024

5.0 stars

Dr. Friedberg is great!

May 03, 2024

5.0 stars

Exceptional / thankful to be under the care of Wilmot Ctr and Dr Friedberg & team

Apr 20, 2024

5.0 stars

Dr. Friedberg is the best, he has saved my life.

Apr 19, 2024

5.0 stars

Best I could have hoped for.

Mar 30, 2024

4.2 stars

I am seeing Dr. Friedberg for a second opinion at the request of another doctor who did not give me accurate information and said we would just watch the lymphoma. I reluctantly took the appointment for a second opinion, although feeling like I was going to waste Dr. Friedbergs time, and then from my understanding samples were not appropriate enough to diagnose, so I am very happy I came to see Dr. Friedberg!! Anna and Carrie are the best! I am hoping all 3 stay with me through this journey, especially when someone is going through this.

Mar 30, 2024

5.0 stars

Dr. Friedberg is an outstanding physician.

Mar 02, 2024

5.0 stars

Excellent doctor

Jan 14, 2024

5.0 stars

He gave me options and together we picked the one best for me

Jan 12, 2024

5.0

Dr. Friedberg is outstanding!

Nov 10, 2023

5.0

Come a long way from recovery and still going forward

Nov 06, 2023

5.0

Dr. Friedberg is the "Best" in my book. He is so knowledgeable, caring, kind, just wonderful!

Sep 07, 2023

5.0

The care I receive from Dr. Friedberg is exceptional and well beyond expectations. He make me feel as if my health and the care I receive is as important to him as it is to me. He is an outstanding medical professional.

Aug 03, 2023

5.0

I'm very fortunate to have this doctor

Jul 21, 2023

5.0

Doctor Friedberg is the best Doctor ever always concerned and always going the extra mile to make sure you understand what he is saying and to make sure you get the best treatment He is truly the most understanding Doctor I have ever met So lucky to have him as my Doctor

Jun 29, 2023

5.0

My doctor treats me like I am his only patient and makes me very comfortable.

Jun 02, 2023

5.0

Dr Friedberg is the best he always makes me feel comfortable and makes me feel I am getting the best care in the world

May 19, 2023

Dr. Friedberg is the model all physicians should aspire to. He not only was lightening fast in responding to my request for advice on my progression, he thoughtfully considered all my concerns. He has eased all my fears and given me great confidence in my path forward.

May 11, 2023

5.0

Takes time to ask if I have any questions and listens!

May 02, 2023

5.0

Provider is a world-leading expert in his field; URMC is lucky to have him.

Apr 18, 2023

5.0

Have recommended this provider and office to people

Dec 29, 2022

5.0

I am very fortunate to have Dr. J. Friedberg as my oncologist.

Dec 29, 2022

5.0

Dr. Friedberg is great!!

Oct 31, 2022

5.0

I love Dr. Friedberg. I always appreciate the time he spends w/me, his compassion, empathy and of course his commitment to CLL.

Oct 27, 2022

5.0

Care provider always informative and willing to listen, and explains things in a clear and concise manner.

Oct 21, 2022

5.0

Dr Friedberg knows my medical history. At this visit he reviewed the results of my CT scan from last week that he ordered My wife had questions about some of the findings and he addressed those questions

Oct 20, 2022

5.0

Doctor Friedberg was the best I have ever had!

Oct 19, 2022

5.0

Everyone at the Wilmot Cancer Center especially my Lymphoma team were thoughtful and focused on my care. I am very appreciatve for everything they did.

Sep 23, 2022

5.0

Dr. Friedberg is Excellent

Sep 15, 2022

5.0

He is the best and I thank him with my life.

Aug 23, 2022

5.0

We are blessed to have Wilmot Ctr.

Aug 19, 2022

5.0

I have decided to be treated at the UpfR verses my home state of California. I can not say enough the doctors spent 75 minutes explaining my diagnosis, prognosis and treatment options.

Jun 30, 2022

5.0

Provider a staff are upbeat and caring during a VERY bad time.

Jun 28, 2022

5.0

Answered all questions to my satisfaction.

May 18, 2022

5.0

Dr. Friedberg is a fine physician and a warm and friendly man. I am lucky to have him as my doctor

Apr 28, 2022

4.6

I was a very good experience, I was scared and they helped me through it. Thank you.

Apr 27, 2022

Dr. Friedberg is thorough and careful to explain options.

Apr 21, 2022

Very thorough and thoughtful

Apr 13, 2022

We covered all the bases that I expected.

Mar 11, 2022

5.0

Great experience.

Feb 21, 2022

4.6

Working through a situation with lots of unknowns--i.e. Covid--and appreciate understanding risks and levels of unknowns

Feb 17, 2022

5.0

All good

Feb 17, 2022

5.0

I have been very satisfied with the overall experience with Dr Friedburg and his team. I was diagnosed in [...] and one of my main worries was too much change and not following what I had already started. I was in luck when I scheduled my first appointment and my fears were quickly put to rest upon completion of my first appointment with Dr. Friedburg and Nurse Anna. They felt the treatment cycle I was on was appropriate and were able to continue and stay on the cycle that I was on already ensuring my treatment continued as if I never switched teams. Thank you for the great experience.

Feb 15, 2022

5.0

I always get the best care

Feb 10, 2022